Items tagged with Treatment
Meropenem plus clavulanate and rifampin for treatment of drug-resistant TB (post)
Results of a study called into question the recommendation for meropenem with amoxicillin and clavulanate to be used as a second-line therapy for drug-resistant tuberculosis (TB). These findings were published in the American Journal of Respiratory and Critical Care Medicine.
Anti-diabetic drug metformin can be used for recovering TB patients: ICMR (post)
The trial aimed to find whether metformin can reduce the time required for sputum culture to become negative in pulmonary TB patients.
Episode 5 of WGND podcast now available online (post)
Episode 5 of the podcast series, The Dose, by the Stop TB Partnership's Working Group on New TB Drugs (WGND) is now available online. Shobha Shukla speaks with two experts on highly drug-resistant TB, Dr. Francesca Conradie and Dr. Gustavo Velásquez, on the results from ZeNix, a Phase 3 clinical trial exploring potential optimization of a regimen for treating patients with highly drug-resistant TB.
Webinar: Discussion of 6-month MDR-TB treatment (post)
RESIST-TB will host a webinar on 14 April 2022 on the latest results in the recent studies reporting on pretomanid-containing regimens, ZeNiX and TB-PRACTECAL, for the treatment of multidrug-resistant TB (MDR-TB).
TB resistance to bedaquiline when it's not reserved as last resource (post)
Bedaquiline-resistant tuberculosis is characterized in South Africa, where it has not been reserved as last resource for drug-resistant TB.
Recently developed drugs for the treatment of drug-resistant TB: a research and development case study (post)
In an article published in the journal BMJ Global Health, authors from the Médecins Sans Frontières (MSF) Access Campaign analyse the development and approval of two newer drugs for treating drug-resistant tuberculosis (DR-TB), bedaquiline and delamanid, in the current pharmaceutical research and development (R&D) paradigm, and the failure of the regulatory approval process to define the drugs’ role in multidrug regimens to improve treatment outcomes.
Webinar: Discussion of 6-month MDR-TB treatment - recording now available online (post)
RESIST-TB conducted a webinar on 14 April 2022 on the latest results in the recent studies reporting on pretomanid-containing regimens, ZeNiX and TB-PRACTECAL, for the treatment of multidrug-resistant TB (MDR-TB).
CDI scientist Dartois co-authors major update on global TB fight (post)
The global effort against tuberculosis, a disease which takes 1.5 million lives annually, presents some cause for optimism, according to an expert from the Hackensack Meridian Center for Discovery and Innovation (CDI) and a colleague from the Harvard T.H. Chan School of Public Health.
Webinar: Treatment of pediatric MDR-TB - lessons from the field (post)
RESIST-TB will host a webinar on 4 May 2022 on the latest childhood treatments and guidelines of the World Health Organization in the pediatric multidrug-resistant TB (MDR-TB) regimens and lessons from the field.
Outcomes, safety of weight-based bedaquiline in children with multidrug-resistant TB (post)
Weight-based dosing of bedaquiline for multidrug/rifampicin-resistant (MDR/RR) tuberculosis (TB) infection was safe and effective among children with and without HIV coinfection, according to findings published in Clinical Infectious Diseases.
Page 63 of 105 · Total posts: 0
←First 62 63 64 Last→